WO2011093186A1 - ピリピロペン生合成遺伝子群およびマーカー遺伝子を含む核酸構築物 - Google Patents
ピリピロペン生合成遺伝子群およびマーカー遺伝子を含む核酸構築物 Download PDFInfo
- Publication number
- WO2011093186A1 WO2011093186A1 PCT/JP2011/050852 JP2011050852W WO2011093186A1 WO 2011093186 A1 WO2011093186 A1 WO 2011093186A1 JP 2011050852 W JP2011050852 W JP 2011050852W WO 2011093186 A1 WO2011093186 A1 WO 2011093186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide sequence
- seq
- pyripyropene
- nucleic acid
- represented
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13008—Flavin-containing monooxygenase (1.14.13.8), i.e. dimethylaniline-monooxygenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
- C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- the present invention relates to a nucleic acid construct comprising a pyripyropene biosynthetic gene group and a marker gene.
- Non-patent Document 1 It has been clarified that 18 types of analogs of pyripyropene A to R exist naturally in the pyripyropene so far due to the difference in the structure of the side chain (Non-patent Document 1).
- Pyripyropene is disclosed to have ACAT inhibitory activity (Patent Document 1), and is expected to be applied to the treatment of diseases caused by cholesterol accumulation.
- moth pilipiropene has an insecticidal activity against giant moth larvae (Non-patent Document 2), long-tailed moth larvae (Patent Document 2), chyllium beetle (Patent Document 2), and aphids (Patent Document 3). Application to insecticide is expected.
- Pyripyropene is known to be produced as a secondary metabolite by filamentous fungi. It is disclosed that -3446 strain (Non-patent document 2) and Penicillium griseofulbum F1959 strain (Patent document 2) each produce pyripyropene.
- pyripyropene Industrial production of pyripyropene is carried out by culturing the above-mentioned producing bacteria and collecting pyripyropene.
- the amount of secondary metabolites produced by microorganisms isolated from nature is very small, and in order to use them industrially, it is necessary to improve the productivity of these objects.
- study the culture method of the target product-producing microorganism study the medium components, improve the fermentation conditions such as the addition of precursors, and mutate with UV irradiation or mutagen. Bacterial strains have been improved. Furthermore, in recent years, productivity has been improved using gene recombination in addition to these methods.
- a general method for improving the productivity by gene recombination is enhancing the expression of biosynthetic genes.
- a method for improving the productivity of the PF1022 substance produced by Agonomycetales by this method is disclosed. (Patent Document 6).
- Patent Document 6 In order to adapt this technique, it is necessary that the target biosynthetic gene has been isolated and a transformation method has been established for the producing microorganism.
- the present inventors have now found that the productivity of pyripyropene is remarkably improved by expressing a nucleic acid construct containing a pyripyropene biosynthetic gene group and a marker gene in a host.
- the present invention is based on such knowledge.
- an object of the present invention is to provide a nucleic acid construct containing a pyripyropene biosynthetic gene group and a marker gene.
- nucleic acid construct comprising a pyripyropene biosynthetic gene group and a marker gene.
- a transformant obtained by introducing the nucleic acid construct into a host.
- a transformant obtained by introducing a nucleic acid construct containing the pyripyropene biosynthetic gene group and a nucleic acid construct containing the marker gene into a host simultaneously or separately. Is provided.
- a method for producing pyripyropene comprising culturing the transformant and collecting pyripyropene from the culture.
- RB represents the right border
- HYG r represents the hygromycin resistance coding region
- PAngpdA represents the Aspergillus nidulans glyceraldehyde triphosphate dehydrogenase promoter ( Aspergillus nidulans glyceraldehyde-3-phosphate dehydrogenase promoter)
- EGFP represents an enhanced green fluorescent protein coding region
- TAngpdA is an Aspergillus nidulans glyceraldehyde triphosphate dehydrogenase terminator ( Aspergillus nidulans glyceraldehyde-3-phosphate dehydrogenase terminater)
- LB represents the left border.
- the left figure shows hygromycin-resistant colonies in the Agrobacterium-infected area, and the right figure shows the result of GFP fluorescence observation.
- the left figure shows a colony of Penicillium copirobium PF1169 strain not infected with Agrobacterium in a medium not containing hygromycin, and the right figure shows the result of GFP fluorescence observation.
- Escherichia coli EPI300 TM -T1 R transformed with the microbial deposit plasmid pCC1-PP1 has been approved by the National Institute of Advanced Industrial Science and Technology (AIST) on October 9, 2008 (original deposit date).
- FERM BP-11133 (transferred from the domestic deposit FERM P-21704) to Tsukuba 1-1-1 Higashi 1-chome Tsukuba, Ibaraki, Japan 305-8856 Japan (indication for identification given by the depositor: Escherichia coli EPI300 TM -T1 R / pCC1-PP1).
- the Escherichia coli transformed with the plasmid pPYRI02 was founded on December 14, 2009 at the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (1st, 1-chome Higashi 1-chome, Tsukuba, Ibaraki, Japan 305-8565). 6), the deposit number is FERM BP-11203 (indication for identification given by the depositor: XL1-Blue MRA / pPYRI02).
- the Escherichia coli transformed with cosmid pPYRI07 is the National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center (December 1, 2010, 1-chome, Higashi 1-chome, Tsukuba City, Ibaraki, Japan 305-8586) 6), the deposit number is FERM BP-11316 (indication for identification given by the depositor: XL1-Blue MRA / pPYRI07).
- the pyripyropene biosynthetic gene group is arranged in a nucleic acid construct in a state that can be expressed in a marker gene and a host described later, and may be a gene group involved in the biosynthesis of pyripyropene.
- a construct comprising the full length or a part of at least one nucleotide sequence selected from the nucleotide sequences described in (I) to (IV) below is provided: (I) a nucleotide sequence from No. 2911 to No. 27797 in SEQ ID No.
- a nucleotide sequence encoding a protein substantially equivalent to the protein to be (III) a polynucleotide having a nucleotide sequence from No. 2911 to No.
- the pyripyropene biosynthesis gene group in the present invention is a gene group comprising a target gene and an expression regulatory region.
- the target gene has one or more genes encoding proteins involved in the biosynthesis of pyripyropene.
- the expression regulatory region is not particularly limited as long as it has a nucleotide sequence necessary for regulating the expression of the target gene in the host. For example, a nucleotide that regulates the transcription amount of the target gene in the host. Sequence promoters and terminators are included.
- the protein involved in the biosynthesis of pyripyropene is, for example, a protein involved in any of the biosynthetic pathways represented by the following scheme 1.
- nucleic acid construct comprising a nucleotide sequence encoding at least one amino acid sequence selected from SEQ ID NOs: 267 to 275 or an amino acid sequence substantially equivalent thereto.
- nucleic acid construct comprising at least one nucleotide sequence selected from the nucleotide sequences described in the following (1) to (4): (1) Nucleotide sequences described in (a)-(i) below: (a) a nucleotide sequence from position 3342 to number 5158 of the nucleotide sequence represented by SEQ ID NO: 266; (b) a nucleotide sequence from 5382 to 12777 of the nucleotide sequence represented by SEQ ID NO: 266, (c) the nucleotide sequence from No. 13266 to No.
- nucleotide sequence represented by SEQ ID NO: 266 15144 of the nucleotide sequence represented by SEQ ID NO: 266, (d) a nucleotide sequence from number 16220 to number 18018 of the nucleotide sequence represented by SEQ ID NO: 266; (e) a nucleotide sequence from number 18506 to number 19296 of the nucleotide sequence represented by SEQ ID NO: 266, (f) a nucleotide sequence from No. 19779 to No.
- nucleotide sequence that is capable of hybridizing under stringent conditions with a complementary sequence of the nucleotide sequence described in (1) and that encodes a protein substantially equivalent to the protein encoded by each nucleotide sequence Array, (3) a polynucleotide comprising the nucleotide sequence described in (1), wherein one or a plurality of nucleotides are deleted, substituted, inserted or added, and the protein encoded by each nucleotide sequence;
- nucleic acid construct comprising at least one nucleotide sequence selected from the nucleotide sequences described in (1) to (4) below: (1) a nucleotide sequence comprising the entire length of the nucleotide sequence described in (a)-(i) or (a)-(h) above, (2) A nucleotide sequence that is capable of hybridizing under stringent conditions with a complementary sequence of the nucleotide sequence described in (1) and that encodes a protein that is substantially equivalent to the protein encoded by the nucleotide sequence , (3) A polynucleotide comprising the nucleotide sequence described in (1), wherein one or a plurality of nucleotides are deleted, substituted, inserted or added, and are substantially the same as the protein encoded by the nucleotide sequence.
- nucleotide sequences encoding identically equivalent proteins (4) a nucleotide sequence which is a nucleotide sequence having at least 90% identity with the polynucleotide comprising the nucleotide sequence described in (1) and which encodes a protein substantially equivalent to the protein encoded by the nucleotide sequence An array.
- nucleic acid construct comprising at least one nucleotide sequence selected from the nucleotide sequences described in the following (1) to (4) is provided: (1) Full length or part of the nucleotide sequence described in (j)-(s) below: (j) Nucleotide sequence from 2911 to 3341 of the nucleotide sequence shown in SEQ ID NO: 266 (k) Nucleotide sequence from 5159th to 5381 of the nucleotide sequence shown in SEQ ID NO: 266 (l) Nucleotide sequence from positions 12778 to 13265 of the nucleotide sequence represented by SEQ ID NO: 266 (m) Nucleotide sequence of nucleotide numbers 15145 to 16219 of the nucleotide sequence shown in SEQ ID NO: 266 (n) the nucleotide sequence of the nucleotide sequence represented by SEQ ID NO: 266 from positions 18019 to 18505 (o
- nucleotide sequence capable of hybridizing under stringent conditions with the nucleotide sequence described in (1) and having a function substantially equivalent to each nucleotide sequence; (3) A polynucleotide comprising the nucleotide sequence described in (1), wherein one or a plurality of nucleotides are deleted, substituted, inserted or added, and are substantially equivalent to each nucleotide sequence. Nucleotide sequence having various functions, (4) A nucleotide sequence having at least 90% identity with the polynucleotide comprising the nucleotide sequence described in (1) and having a function substantially equivalent to each nucle
- a nucleic acid construct comprising at least one nucleotide sequence selected from the nucleotide sequences described in the following (1) to (4) is provided: (1) a nucleotide sequence comprising all the full length of the nucleotide sequence described in (j)-(s) or (j)-(r), (2) a nucleotide sequence capable of hybridizing under stringent conditions with the nucleotide sequence described in (1) and having a function substantially equivalent to each nucleotide sequence; (3) A polynucleotide comprising the nucleotide sequence described in (1), wherein one or a plurality of nucleotides are deleted, substituted, inserted or added, and are substantially equivalent to each nucleotide sequence. Nucleotide sequence having various functions, (4) A nucleotide sequence having at least 90% identity with the polynucleotide comprising the nucleotide sequence described in (1) and having a function substantially equivalent to each nucleotide sequence.
- the full length or a part of the biosynthetic gene cluster derived from the pyripyropene-producing bacterium can be isolated and used, preferably, Penicillium copyrobium PF1169 represented by SEQ ID NO: 266.
- the full length or part of the derived pyripyropene biosynthetic gene cluster can be used, and more preferably, the full length of the pyripyropene biosynthetic gene cluster derived from Penicillium copirobium PF1169 strain represented by SEQ ID NO: 266 can be used.
- a “substantially equivalent amino acid sequence” means an amino acid sequence that has a modification by substitution, deletion, addition, or insertion of one or more amino acids, but does not affect the activity of the polypeptide.
- the amino acid sequence modified by amino acid substitution, deletion, addition, or insertion is 70% or more, preferably 80% or more, more preferably 90% or more, still more preferably with respect to the amino acid sequence before the modification or the like. Preferably have a sequence identity of 95% or more, even more preferably 98% or more.
- the number of amino acid residues to be modified is preferably 1 to 40, more preferably 1 to 20, more preferably 1 to 10, still more preferably 1 to 8, and most preferably 1 to 4. It is a piece.
- modifications that do not affect activity include conservative substitutions.
- the “conservative substitution” is preferably 1 to 40, more preferably 1 to 20, still more preferably 1 to 10, even more preferably 1 to 1, so as not to substantially change the activity of the polypeptide. It means that 8 and most preferably 1 to 4 amino acid residues are replaced by another chemically similar amino acid residue. For example, when a certain hydrophobic amino acid residue is substituted by another hydrophobic amino acid residue, a certain polar amino acid residue is substituted by another polar amino acid residue having the same charge, and the like. Functionally similar amino acids that can make such substitutions are known in the art for each amino acid.
- nonpolar amino acids such as alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, and methionine.
- polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, cysteine and the like.
- positively charged (basic) amino acids include arginine, histidine, and lysine.
- negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- “strict conditions” means that the membrane washing operation after hybridization is performed in a high-temperature, low-salt concentration solution, and those conditions can be appropriately determined by those skilled in the art.
- 2 ⁇ SSC concentration (1 ⁇ SSC: 15 mM trisodium citrate, 150 mM sodium chloride), washing condition in 0.5% SDS solution at 60 ° C. for 20 minutes, or 0.2 ⁇ SSC concentration (1 ⁇ SSC: 15 mM trisodium citrate, 150 mM sodium chloride), in a 0.1% SDS solution means washing conditions at 60 ° C. for 15 minutes.
- Hybridization can be performed according to a known method. Moreover, when using a commercially available library, it can carry out according to the method as described in an attached instruction manual.
- identity (sometimes referred to as homology) with respect to nucleotide sequences is used to mean the degree of coincidence of bases constituting each sequence among the sequences to be compared. At this time, the existence of gaps and the nature of amino acids are considered. Any numerical value of “identity” shown in the present specification may be a numerical value calculated using a homology search program known to those skilled in the art. For example, a default (initial setting) parameter in FASTA, BLAST, or the like. Can be easily calculated.
- the “identity” with respect to the nucleotide sequence is 90% or more, preferably 95% or more, more preferably 98% or more, and further preferably 99% or more.
- nucleotides are deleted, substituted, inserted or added in a polynucleotide” may occur by a known method such as site-directed mutagenesis or naturally. It means that the modification was made by substitution of a plurality of nucleotides or the like.
- the number of nucleotide modifications is one or more (for example, one to several, 1, 2, 3, or 4).
- Nucleotide sequence encoding a protein substantially equivalent to the protein encoded by each nucleotide sequence means that the activity equivalent to “a protein encoded by each nucleotide sequence” has the same activity. It means a nucleotide sequence encoding a protein having the same.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from No. 3342 to No. 5158 of the nucleotide sequence represented by SEQ ID NO: 266 has CoAligase activity.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 5382 to 12777 of the nucleotide sequence shown in SEQ ID NO: 266 has LovB-like polyketide synthase (PKS) activity Is preferred.
- PKS LovB-like polyketide synthase
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 13266 to 15144 of the nucleotide sequence represented by SEQ ID NO: 266 has the activity of Cytochrome P450 monooxygenase (cytochrome P450 monooxygenase) (1) (P450-1) It is preferable to have.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 16220th to 18018th of the nucleotide sequence represented by SEQ ID NO: 266 has Cytochrome P450 monooxygenase (2) (P450-2) activity.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 18506 to 19296 of the nucleotide sequence represented by SEQ ID NO: 266 preferably has Cyclase (IMP: Integral membrane protein) activity.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence of the nucleotide sequence 19779 to 21389 of the nucleotide sequence represented by SEQ ID NO: 266 may have FAD-dependent monooxygenase (FMO-dependent monooxygenase) (FMO) activity preferable.
- FMO-dependent monooxygenase FMO-dependent monooxygenase
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 21793 to 22877 of the nucleotide sequence represented by SEQ ID NO: 266 preferably has UbiA-like prenyltransferase (UbiA-like prenyltransferase) (UbiAPT) activity. .
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 23205 to 24773 of the nucleotide sequence represented by SEQ ID NO: 266 has Acetyltransferase (AT) activity.
- a protein substantially equivalent to the protein encoded by the nucleotide sequence from 25824 to 27178 of the nucleotide sequence represented by SEQ ID NO: 266 has acetyltransferase-2 (AT-2) activity.
- Nucleotide sequence having substantially the same function as each nucleotide sequence is not particularly limited as long as it has a function equivalent to “each nucleotide sequence”.
- the function to regulate the expression of the target gene is equivalent. Specifically, it means that functions such as promoter activity and terminator activity are equivalent.
- the target gene and expression control region are synthesized by a suitable primer based on the nucleotide sequence, and DNA amplification by PCR using a genomic DNA derived from a pyripyropene-producing bacterium or the like as a template or chemically It can be obtained by total synthesis.
- pyripyropene is used in the meaning including from pyripyropene A to R, preferably pyripyropene A, E, and O, and more preferably pyripyropene A.
- the pyripyropene biosynthetic gene group can be isolated, for example, by the following method. For example, genomic DNA of a pyripyropene-producing bacterium is extracted, cleaved with an appropriate restriction enzyme, and a library composed of genomic DNA is prepared using a cosmid vector. Subsequently, an appropriate primer was synthesized based on the nucleotide sequence contained in the pyripyropene biosynthesis gene group such as cytochrome P450 as described in Example 12, and PCR was performed using the genomic DNA derived from the pyripyropene-producing bacterium as a template.
- the method is carried out to amplify a DNA fragment comprising a part of a biosynthetic gene group. Using this DNA fragment as a probe, a genomic library can be screened to isolate the full-length or part of the pyripyropene biosynthetic gene group.
- the pyripyropene biosynthetic gene group expressed in the host in the present invention can be obtained by linking an expression regulatory region functioning in the host to the target gene, in addition to the above method.
- the target gene and expression regulatory region may be linked by any method as long as the target gene is expressed in the host. For example, a method of operably linking a promoter upstream of the target gene and a terminator downstream. There is.
- the target gene and the expression regulatory region according to the present invention can be linked according to a known method.
- the marker gene according to the present invention is arranged in a nucleic acid construct in a state that can be expressed in the above-described pyripyropene biosynthetic gene group and host, and can be appropriately selected according to the selection method of the transformant.
- Genes that encode drug resistance and genes that complement auxotrophy can be used.
- drug resistance genes include genes for drugs such as destomycin, hygromycin, benomyl, oligomycin, G418, bleomycin, bialaphos, blasticidin S, phleomycin, phosphinothricin, ampicillin, kanamycin, and the like. Includes a destomycin resistance gene or a hygromycin resistance gene.
- genes that complement auxotrophy include genes such as amdS , pyrG , argB , trpC , niaD , TRP1 , LEU2 , and URA3 .
- marker genes can be used after being isolated, amplified, or synthesized, for example, in the same manner as the pyripyropene biosynthetic genes.
- nucleic acid construct of the present invention may be in any form as long as it can be introduced into a host gene, but preferably it can be used in a form incorporated into a vector upon introduction into the host. Therefore, according to a preferred embodiment of the present invention, there is provided a recombinant vector comprising the nucleic acid construct according to the present invention.
- the recombinant vector according to the present invention can be prepared by introducing a pyripyropene biosynthetic gene group and a marker gene expressed in a host into an appropriate vector.
- Any vector can be used in the present invention as long as it can be introduced into a host.
- Examples thereof include cosmids, phage vectors, pUC plasmids, pBluescript plasmids, and pBR322 plasmids.
- Hosts that can be used in the present invention are not particularly limited as long as they can produce a pyripyropene by introducing the nucleic acid construct of the present invention, but microorganisms that can produce pyripyropene even without introducing the nucleic acid construct of the present invention are preferable, More preferred are filamentous fungi, still more preferred are microorganisms belonging to the genus Penicillium, Eupenicillium, or Aspergillus, and still more preferred are Penicillium copyrobium, Penicillium griseofulbum, Eupenicillium reticulosporum, or Aspergillus fumigatus Among these, Penicillium copirobium is preferable, and Penicillium copirobium PF1169 strain is most preferable.
- the host by transforming with the nucleic acid construct, a transformant pyripyropene biosynthesis genes has been introduced, it is provided.
- the method for introducing the nucleic acid construct into the host is not particularly limited as long as it is introduced into the host.
- the nucleic acid construct can be introduced into the host by the following method using a recombinant vector.
- Introduction of a nucleic acid construct using a recombinant vector into a host can be performed according to a conventional method.
- the introduction method include an electroporation method, a polyethylene glycol method, an Agrobacterium method, a lithium method, and a calcium chloride method, and a method that is efficient for the host cell is selected.
- the polyethylene glycol method is preferred.
- plasmid pPYRI02 (Accession number of E. coli transformed with plasmid pPYRI02: FERM BP-11203) or cosmid pPYRI07 (Accession number of E. coli transformed with cosmid pPYRI07: FERM BP-11316)
- a transformant obtained by introducing A into a host is provided.
- a method for producing a pyripyropene comprising culturing the transformant produced as described above and collecting the pyripyropene from the culture, preferably A mass production method is provided.
- the transformant can be cultured according to a conventional method by appropriately selecting a medium, culture conditions and the like.
- a medium conventional components such as glucose, sucrose, cellulose, starch syrup, dextrin, starch, glycerol, molasses, animal / vegetable oil, etc. can be used as the carbon source.
- the nitrogen source soybean flour, wheat germ, pharma media, corn steep liquor, cottonseed meal, bouillon, peptone, polypeptone, malto extract, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used.
- inorganic salts capable of producing sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphoric acid, sulfuric acid and other ions as required, such as potassium chloride, calcium carbonate, dipotassium hydrogen phosphate, magnesium sulfate, It is also effective to add 1 potassium phosphate, zinc sulfate, manganese sulfate, and copper sulfate.
- various vitamins such as thiamine (thiamine hydrochloride, etc.), amino acids such as glutamic acid (sodium glutamate), asparagine (DL-asparagine, etc.), micronutrients such as nucleotides, and selective drugs such as antibiotics are added as necessary. You can also Furthermore, organic substances and inorganic substances that assist the growth of bacteria and promote the production of pyripyropene can be appropriately added.
- the culture method can be carried out by a shaking culture method under aerobic conditions, an aeration stirring culture method or a deep aerobic culture method, and the aeration stirring culture method is most suitable.
- the pH of the medium is, for example, about pH 6 to pH 8.
- a suitable temperature for culturing is 15 ° C. to 40 ° C., but in many cases grows at around 26 ° C. to 37 ° C.
- the production of pyripyropene varies depending on the medium and culture conditions, or the host used, but in any culture method, its accumulation usually reaches its maximum in 2 to 25 days.
- Cultivation is stopped when the amount of pyropyropene during culture reaches the maximum, and pyropyropene is collected from the culture and isolated and purified as necessary.
- pyropyropene is collected from the culture and isolated and purified as necessary.
- multiple types of pyropyropene may be collected at the same time and isolated and purified as necessary, or multiple types of pyropyropene may be collected separately. If necessary, isolation and purification may be performed.
- Example 1 Preparation of Penicillium copirobium PF1169 strain genomic DNA 500 ml of sterilized NB medium was placed in an Erlenmeyer flask (1 L) and penicillium copirobium PF1169 strain (previously cultured at 28 ° C. for 4 days in 1/2 CMMY agar medium ( Published technical report 2008-500997 (Patent Document 4) was added to the above medium, and liquid culture was performed at 28 ° C. for 4 days. Filtration with Miracloth gave 5 g of bacterial cells. From this bacterial cell, a genomic DNA purification kit Genomic-tip 100 / G (manufactured by Qiagen Co., Ltd.) was obtained according to the attached manual to obtain 30 ⁇ g of genomic DNA.
- Genomic-tip 100 / G manufactured by Qiagen Co., Ltd.
- Example 2 Degenerate primer for polyketide synthase (PKS) amplification and amplified fragments
- PPS polyketide synthase
- LC1 GAYCCIMGITTTYTYAYAYATG
- Example 1 Using this degenerate primer, the genomic DNA prepared in Example 1 was reacted with ExTaq polymerase (manufactured by Takara Bio Inc.) according to the attached manual to detect an amplified fragment of about 700 bp (FIG. 1). . Then, the amplified fragment was analyzed, and an internal 500 bp sequence was identified (SEQ ID NO: 3).
- Example 3 Genomic DNA Mass Sequence and Amino Acid Sequence Homology Search
- the genomic DNA of Penicillium copirobium PF1169 obtained in Example 1 was subjected to mass sequencing and amino acid sequence homology search. Specifically, a portion of 50 ⁇ g of genomic DNA was pretreated and then subjected to a Roche 454 FLX DNA sequencer to obtain about 250 bp, 103,000 fragment sequences (total 49 Mb sequence).
- polyketide synthase Aspergillus (A.) fumigatus PKS 2146a.a. And Penicillium (P.) griseofluvum 6-methylsalycilic ) are known as polyketide synthase and prenyltransferase .
- prenyltransferase Aspergillus (A.) fumigatus Prenyltransferase, Aspergillus (A.) fumigatus Prenyltransferase (4-hydroxybezoate octaprenyltransferase), and Penicillium (P.) marneffei Prenyltransferase )
- a search using the search software blastx was performed. 89, 86, 2, 1, and 3 homologous sequences were obtained, respectively (see Table 2). Furthermore, 19 and 23 contig sequences were obtained from the homologous sequences of A. fumigatus PKS 2146a.a. And P.
- griseofluvum 6-methylsalycilic acid synthase 1744a.a. A. fumigatus PKS 2146a.a. Contig sequence: SEQ ID NO: 179 to 197, Contig sequence of P. griseofluvum 6-methylsalycilic acid synthase 1744a.a. (SEQ ID NO: 198 to 220) (see Table 2).
- Example 4 PCR amplification from genomic DNA From the search results of blastx obtained in Example 3, 13 types of primer pairs shown in SEQ ID NOs: 227 to 252 were synthesized for polyketide synthase. Similarly, five kinds of primer pairs shown in SEQ ID NOs: 253 to 262 were synthesized for prenyltransferase. When PCR was performed on genomic DNA using these primers, amplified fragments of the expected size were recognized for all primer pairs (see FIGS. 1 and 2).
- Example 5 Preparation of phage genomic library A ⁇ phage genomic library of Penicillium copirobium PF1169 strain was attached using ⁇ BlueSTAR Xho I Half-site Arms Kit (Takara Bio Inc. Cat. No. 69242-3). Constructed according to the manual. That is, genomic DNA was partially decomposed using the restriction enzyme Sau3A1, and 0.5 ⁇ g of a DNA fragment of about 20 kb was ligated to 0.5 ⁇ g of ⁇ BlueSTAR DNA attached to the kit.
- This ligation solution was subjected to in vitro packaging using a Lambda INN Packaging kit (manufactured by Nippon Gene Co., Ltd.) according to the manual attached to the kit to obtain 1 ml of the solution.
- 10 ⁇ l of this packaged phage solution was infected with 100 ⁇ l of E. coli ER1647 strain, and after culturing overnight at 37 ° C. in a plaque forming medium, about 500 clone plaques were obtained.
- a genomic library consisting of about 50,000 phages into which genomic DNA of 10-20 kb Penicillium copirobium PF1169 strain was introduced by infection was prepared.
- Example 6 Screening from phage library Primary PCR hybridization using the PCR product amplified with the LC1-LC2c primer pair prepared above as a probe for the 10,000 phage library clone prepared in Example 5 Screening was performed. AlkPhos Direct Labeling and Detection System with CDP-Star (Cat. No. RPN3690, manufactured by GE Healthcare) was used for labeling and detection of the probe. The hybridization was performed according to the attached manual.
- Example 7 Preparation of fosmid genomic library
- a genomic library of Penicillium copirobium PF1169 strain was constructed by CopyControl Fosmid Library Production Kit (EPICENTRE, Cat. No. CCFOS110) according to the attached manual. That is, a DNA fragment of 0.25 ⁇ g of about 40 kb genomic DNA was blunt-ended and then incorporated into a fosmid vector pCCFOS (Epicentre).
- This ligation solution was packaged in vitro using MaxPlax Lambda Packaging Extract attached to the kit based on the manual attached to the kit. When 10 ⁇ l of this packaged virus solution was infected with 100 ⁇ l of E. coli EPI300 TM -T1 R strain and cultured overnight at 37 ° C.
- Example 8 Fosmid library screening According to the manual attached to the fosmid, each plasmid DNA was prepared from 96 pools of the library prepared in Example 7. Using the polyketide synthetase amplification degenerate primers synthesized in Example 2, PCR was performed on the 96 pool plasmid DNA samples. As a result, a DNA fragment of about 700 bp was amplified from 9 pools. Furthermore, a petri dish containing colonies of about 300 clones or more was prepared from this positive pool and rescreened by colony hybridization. As a result, nine fosmids were obtained from about 4800 clones using the LC1-LC2c primer pair.
- Example 9 Mass sequence of genomic DNA and amino acid sequence homology search
- the genomic DNA of Penicillium copirobium PF1169 strain obtained in Example 1 was subjected to mass sequence and amino acid sequence homology search. Specifically, 50 ⁇ g of genomic DNA was pretreated and then subjected to a Roche 454 FLX DNA sequencer to obtain an average contig length of 19.621 kb and a fragment sequence of 1405 fragments (total base length of 27.568160 Mb). The following five sequences (polyketide synthase: Penicillium (P.) Griseofluvum 6-methylsalycilic acid synthase 1744a.a.
- P22367 and Aspergillus ( P22367) and Aspergillus ( P22367) are known as polyketide synthase and prenyltransferase.
- Example 10 Fosmid library screening and cluster gene sequence analysis According to the manual attached to the Fosmid kit (CopyControl Fosmid Library Production Kit manufactured by EPICENTRE), each plasmid from 96 pools of the library prepared in Example 7 DNA was prepared. Based on the nucleotide sequence determined by the Roche 454FLX DNA sequencer, a homology search of amino acid sequences was performed to search for a region where polyketide synthase and prenyltransferase are close to each other. A primer pair (No. 27) capable of amplifying a 400 bp DNA fragment was synthesized from the prenyltransferase base sequence in the obtained region. Using this primer, PCR was performed on the 48 pools of plasmid DNA samples.
- an expected DNA fragment of about 400 bp (SEQ ID NO: 263) was amplified from 11 pools (see FIG. 3). Furthermore, a petri dish containing colonies of about 300 clones or more was prepared from 6 of the positive pools and rescreened by colony hybridization. As a result, 4 types of fosmids were obtained from about 4800 clones using 27F + 27R primer pairs (27F primer: SEQ ID NO: 264), 27R primer: SEQ ID NO: 265)). One of these was named pCC1-PP1 and the entire sequence of the insert was determined (SEQ ID NO: 266)).
- Escherichia coli EPI300 TM -T1 R strain (attached to the fosmid kit) with the obtained pCC1-PP1, Escherichia coli EPI300 TM -T1 R strain / pCC1-PP1 (accession number FERM BP-11133) Got.
- SEQ ID NO: 266 CoA ligase, LovB-like polyketide synthase (PKS), hydroxylase Cytochrome P450 monooxygenase, Cyclase, FAD-dependent monooxygenase (FMO), UbiA-like prenyltransferase (UbiAPT), acetylation
- a homology search with the enzymes Acetyltransferase (AT), Acetyltransferase-2 (AT-2), and Cation transporting ATPase all of the above-mentioned enzymes are derived from Aspergillus fumigatus Af293 strain was performed. The above high homology was shown.
- Nucleotides 3342-5158 of SEQ ID NO: 266 encode CoA ligase, and the corresponding polypeptide is represented by the amino acid sequence set forth in SEQ ID NO: 267, and nucleotides 5382-12777 of SEQ ID NO: 266 are LovB-like polyketide synthase
- the corresponding polypeptide encoding (PKS) is represented by the amino acid sequence set forth in SEQ ID NO: 268 and is encoded by nucleotides 13266-15144 of SEQ ID NO: 266 (hereinafter, this polynucleotide sequence (P450-1)).
- Cytochrome P450 monooxygenase (1)) and 16220-18018 (hereinafter, the protein encoded by this polynucleotide sequence (P450-2) is referred to as Cytochrome P450 monooxygenase (2)) encodes Cytochrome P450 monooxygenase,
- the corresponding polypeptide is SEQ ID NO: 26, respectively.
- nucleotide 18506-19296 of SEQ ID NO: 266 encodes Cyclase and the corresponding polypeptide is shown by the amino acid sequence set forth in SEQ ID NO: 271 and nucleotide 19779 of SEQ ID NO: 266.
- -21389 encodes FAD-dependent monooxygenase (FMO), and the corresponding polypeptide is represented by the amino acid sequence set forth in SEQ ID NO: 272, and nucleotide 21793-22877 of SEQ ID NO: 266 is a UbiA-like prenyltransferase (UbiAPT)
- the corresponding polypeptide is represented by the amino acid sequence set forth in SEQ ID NO: 273, nucleotides 23205-24773 of SEQ ID NO: 266 encodes acetyltransferase (AT), and the corresponding polypeptide is represented by SEQ ID NO: 274.
- the amino acid sequence described is shown in SEQ ID NO: 266.
- Leotide 25824-27178 encodes Acetyltransferase-2 (AT-2), and the corresponding polypeptide is represented by the amino acid sequence set forth in SEQ ID NO: 275, and nucleotides 27798-31855 of SEQ ID NO: 266 is a Cation transporting ATPase. The encoded and corresponding polypeptide was shown with the amino acid sequence set forth in SEQ ID NO: 276.
- Example 11 Preparation of genomic DNA library A cosmid vector pMFCOS1 capable of transformation of fungi was constructed as follows. An approximately 3.0 kb Xba I fragment containing a destomycin resistance gene which is a marker gene for mold transformation was prepared from plasmid pMKD01 (Japanese Patent No. 3593134), and the ends were blunted using T4 polymerase. This fragment was ligated with a commercially available cosmid vector SuperCos1 (Stratagene) double digested with restriction enzymes Sma I and Stu I to construct cosmid vector pMFCOS1.
- Penicillium copirobium PF1169 strain (open technical report No. 2008-500997 (Patent Document 4)), which is a pyripyropene A-producing bacterium, was added to a liquid medium (3% glycerin, 0.8% neutral broth, 0.3% malt extract, 0.2% yeast extract, 0.1% sodium glutamate, pH 7.0) and inoculated at 26 ° C. for 48 hours. After completion of the culture, the cells were collected by centrifugation, and chromosomal DNA was prepared from these cells. Chromosomal DNA was partially digested with the restriction enzyme Sau3AI and then treated with alkaline phosphatase to dephosphorylate the DNA ends.
- a liquid medium 3% glycerin, 0.8% neutral broth, 0.3% malt extract, 0.2% yeast extract, 0.1% sodium glutamate, pH 7.0
- This DNA fragment was digested with restriction enzyme Xba I in advance and dephosphorylated by alkaline phosphatase treatment, and further ligated to cosmid vector pMFCOS1 digested with restriction enzyme Bam HI to prepare a recombinant cosmid vector.
- This recombinant cosmid vector was packaged in vitro using MAXPLAX lambda packaging extract manufactured by Epicenter, and infected with E. coli XLI-Blue MRA to prepare a genomic DNA library.
- Example 12 Screening of genomic DNA library As a probe for screening the genomic DNA library prepared in Example 1, the cytochrome P450 gene, which is one of the pyripyropene A biosynthetic genes, was used and is shown below. As prepared by PCR.
- PCR was carried out using the genomic DNA shown in Example 1 as a template and oligo DNAs of 5'-ATGATCGAGCTCAAAGATGC-3 '(SEQ ID NO: 277) and 5'-CTTCTTTCCAGTCAATACCT-3' (SEQ ID NO: 278) as primers.
- PCR was performed using PERKIN ELMER GeneAmp PCR System 9700 using Prime® STAR® HS® DNA® polymerase (Takara Bio Inc.) as a DNA polymerase.
- the primer was prepared by adjusting the genomic DNA to 0.5 ⁇ l (corresponding to 0.5 ⁇ g), the double-concentration reaction buffer attached to the enzyme to 25 ⁇ l, the 2.5 mM dNTP solution to 4 ⁇ l, and the concentration of 100 pmol / ⁇ l.
- 0.5 ⁇ l each, 0.5 ⁇ l of enzyme and 19 ⁇ l of sterilized water were added to make 50 ⁇ l.
- the reaction was conducted at 94 ° C. for 5 minutes, followed by 25 cycles of incubation at 98 ° C. for 10 seconds, 50 ° C. for 5 seconds, and 72 ° C. for 2 minutes. After completion of the reaction, a part of the reaction solution was subjected to agarose gel electrophoresis.
- Example 13 Production of transformants Penicillium copirobium PF1169 strain, which is a pyripyropene-producing bacterium, was added to a liquid medium (3% glycerin, 0.8% nutritive broth, 0.3% malt extract, 0.2% yeast extract, 0.1% sodium glutamate, 2.0% Glycine, pH 7.0) was inoculated and cultured at 26 ° C. for 24 hours, and then the cells were collected by centrifugation.
- a liquid medium 3% glycerin, 0.8% nutritive broth, 0.3% malt extract, 0.2% yeast extract, 0.1% sodium glutamate, 2.0% Glycine, pH 7.0
- the obtained microbial cells were washed with 1.0 M KCl and filtered through a 0.45 ⁇ m filter, and the protoplastizing enzyme solution (3 mg / mL ⁇ -glucuronidase, 1 mg / mL Chitinase, 3 mg / mL Lysing enzyme, 1.0 M KCl) Suspended in 10 mL. The hyphae were protoplasted by shaking at 30 ° C. for 60-90 minutes. The suspension was filtered and then centrifuged to collect protoplasts, which were then washed with a SUTC buffer (0.5 mol / L sucrose, 10 mM calcium chloride, 10 mM Tris-HCl [pH 7.5]).
- a SUTC buffer 0.5 mol / L sucrose, 10 mM calcium chloride, 10 mM Tris-HCl [pH 7.5]
- the prepared protoplast was suspended in 1 mL of SUTC buffer, 10 ⁇ g of pPYRI02 DNA solution (20 ⁇ L) was added to 100 ⁇ L of this, and the mixture was allowed to stand on ice for 5 minutes. Next, 400 ⁇ L of PEG solution (60% PEG 4000, 10 mM calcium chloride, 10 mM Tris-HCl [pH 7.5]) was added and mixed, allowed to stand in ice for 20 minutes, 10 mL of SUTC buffer was added, and the mixture was centrifuged. Protoplast cells were collected. The obtained bacterial cells were suspended in 1 mL of SUTC buffer, centrifuged at 4000 rpm for 5 minutes, and finally suspended in 100 ⁇ L of SUTC buffer.
- PEG solution 50% PEG 4000, 10 mM calcium chloride, 10 mM Tris-HCl [pH 7.5]
- the cells subjected to the above treatment were layered on a 200 ⁇ g / mL hygromycin B, 1.0 M sucrose-containing potato dextrose agar together with a soft 1.0 M sucrose-containing potato dextrose agar medium, and cultured at 26 ° C. for 4 days. Thereafter, the formed colonies were used as transformants.
- Example 14 Transformant culture and quantification of pyripyropene in culture medium
- a medium (pH 7.0 before sterilization) having a composition of% polypeptone, 0.6% wheat germ, 0.3% yeast extract, 0.2% soybean meal and calcium carbonate 0.2% was used.
- 10.0% glucose, 1.3% defatted soybean, 0.3% sodium glutamate, 0.8% wheat germ, 0.125% sodium chloride, 0.15% calcium carbonate 0.00%
- a medium having a composition of 2% nicotinamide (pH 7.0 before sterilization) was used.
- the 250 ml Erlenmeyer flask into which 40 ml of the seed medium was dispensed was sterilized at 122 ° C. for 20 minutes, and the transformant described in Example 13 was inoculated with 1 platinum loop of fungus and then shaken at 26 ° C. for 3 days. Cultured.
- a 250 ml Erlenmeyer flask into which 20 ml of production medium had been dispensed was sterilized at 122 ° C. for 20 minutes, and 0.5 ml of the seed culture solution was aseptically transplanted thereto, and cultured with shaking at 26 ° C. for 8 days.
- the obtained pattern was compared with a pyripyropene standard product, a peak derived from pyripyropene was identified, and pyripyropene was quantified from the area.
- the pyripyropene analogs that were quantified were pyripyropene A, E, and O produced in this bacterium.
- the penicillium copirobium 1 PF1169 strain which is the parent strain of the transformant, was similarly cultured and quantified for pyripyropene in the culture solution.
- Example 15 Transformation of Penicillium copirobium using Agrobacterium tumefaciens
- Penicillium copirobium PF1169 strain was cultured for 3 days at 28 ° C on 1 / 2CMMY agar medium, and conidia was scraped off and collected. Spores were obtained by filtration through sterile Miracloth (Carbiochem, Cat, No.
- IM liquid medium (1.74 g / L K 2 HPO 4 , 1.36 g / L KH 2 PO 4 , 0.14 g / L NaCl, 0.49) g / L MgSO 4 ⁇ 7H 2 O, 0.10 g / L CaCl 2 ⁇ 2H 2 O, 100 ⁇ L / L 9 mM FeSO 4 , 0.53 g / l (NH 4 ) 2 SO 2 , 1.8 g / L glucose, 8.53 g / L MES (2-Morpholinoethanesulfonic acid), 5 mL / L glycerin, pH 5.3) was diluted to 10 3 / ml, and this was made into a Penicillium copirobium spore suspension.
- Agrobacterium tumefaciens strain EHA105 introduced with pBI-AnGPD-EGFP (RIKEN) shown in Fig. 4 is inoculated into IM liquid medium containing 50 ppm kanamycin (Km) and cultured at 28 ° C overnight. did.
- This is diluted with IM liquid medium containing 50 ppm of Km so that the absorption of transmitted light at 660 nm is 0.3 to 0.45, acetosyringone (AS) is added to a final concentration of 500 ⁇ M, and 28 Culturing was carried out at ° C for 6 hours, and this was used as an Agrobacterium culture solution.
- Co-cultivation agar medium (1.74 g / L K 2 HPO 4 , 1.36 g / L KH 2 PO 4 , 0.14 g / L NaCl, 0.49 g / L MgSO 4 ⁇ 7H 2 O containing 50 ppm Km and 500 ⁇ M AS , 0.10 g / L CaCl 2 ⁇ 2H 2 O, 100 ⁇ L / L 9 mM FeSO 4 , 0.53 g / l (NH 4 ) 2 SO 2 , 0.9 g / L glucose, 8.53 g / L MES (2-Morpholinoethanesulfonic acid) , 5 mL / L glycerin, 15 g / L Agar, pH 5.3) and hybond-N + (GE Health Science, diameter 82 mm, Cat.
- Example 16 Screening of genomic DNA library 2
- the base sequence at the end of the inserted fragment of pPYRI02 obtained in Example 12 is a sequence including 1-25000 of SEQ ID NO: 266 and its upstream region. Further, in order to obtain a full-length pyripyropene biosynthetic gene cluster to which the downstream part of the pyripyropene biosynthetic gene cluster is added, the downstream part of the biosynthetic gene cluster separately cloned and the inserted fragment of pPYRI02 described above are linked. We decided to construct a synthetic gene cluster.
- the O-acetyltransferase gene which is a pyripyropene A biosynthetic gene not included in pPYRI02, was used as a probe from the genomic DNA library prepared in Example 11. The part was cloned.
- pPYRI02 insert fragment obtained in Example 12 was constructed using the pPYRI02 insert fragment obtained in Example 12 and the pPYRI03 insert fragment.
- Analysis of the base sequence of each cosmid reveals the restriction enzyme site on the cluster.
- the Bsi WI fragment (approximately 20.2 kb) of pPYRI02 is the upstream region of the biosynthetic gene cluster, and the Bsi WI to Afl of pPYRI03 is the downstream region. It was revealed that a full-length biosynthetic gene class can be constructed by linking II fragments (about 4.9 kb). Therefore, first, plasmid pSET152 for actinomycete conjugation transmission [Bierman, M.
- Hin-Not-Bsi-Afl-Not-Eco-1 5'-AGCTTGCGGCCGCGTACGCTTAAGGCGGCCGCG-3 ') to change the multi-cloning site of pSET153 to Hin dIII- Not I- Bsi WIAflII- Not I- Eco RI after annealing (SEQ ID NO: 282) and Hin-Not-Bsi-Afl- Not-Eco-2 (5'-AATTCGCGGCCGCCTTAAGCGTACGCGGCCGCA-3 ') ( SEQ ID NO: 283), and pSET153 was double-digested with Hin dIII and Eco RI
- the plasmid pSET201 was constructed by ligation.
- the plasmid pPYRI05 was obtained by inserting an approximately 4.9 kb Bsi WI-Afl II fragment derived from pPYRI03 into the Bsi WI-Afl II site of pSET201.
- a Bsi WI site of PPYRI05 insert the Bsi WI fragment of about 20.2kb from PPYRI02, it was selected clones Bsi WI fragment had been inserted in the biosynthesis gene cluster in the same direction of natural, to obtain a plasmid PPYRI06.
- pPYRI06 is a plasmid containing the entire biosynthetic gene cluster, it does not have a fungal transformation marker. Therefore, the insert fragment was transferred to the cosmid vector pMFCOS1.
- cosmid pPYRI07 is a cosmid that contains the entire biosynthetic gene cluster and also has a fungal transformation marker gene.
- Example 17 Production of transformant using pPYRI07 A transformant was produced under the same conditions as in Example 13 except that pPYRI07 obtained in Example 16 was used.
- Example 18 Transformant culture and quantification of pyripyropene in the culture solution
- the transformant obtained in Example 17 and the method of quantification of pyripyropene in the culture solution were the same as those shown in Example 14. .
- the pyripyropene analogs that were quantified were pyripyropene A, E, and O produced in this bacterium.
- Penicillium copirobium PF1169 which is the parent strain of the transformant, was similarly cultured and quantified for pyripyropene in the culture broth.
- Table 4 shows that the pyripyropene productivity of the transformant was improved 3.6 times that of the parent strain. From the above results, it was shown that the introduction of the full-length pyripyropene biosynthetic gene cluster improves the productivity of Penicillium copirobium PF1169 strain.
- Example 19 Production of transformant using penicillium copyrobium Penicillium copyrobium
- Penicillium copyrobium In order to confirm that the productivity of penicillium copyrobium other than PF1169 strain is improved by introducing a full-length pyripyropene biosynthetic gene cluster.
- Copirobium ATCC58615 strain (see Studies in Mycology (2004), 49 p84-85) was transformed.
- a transformant was produced in the same manner as the method shown in Example 13, except that pPYRI07 obtained in Example 16 was used.
- Example 20 Cultivation of transformant and quantification of pyripyropene in culture medium
- the culture of the transformant obtained in Example 19 and the method of quantification of pyripyropene in the culture liquid were carried out except that the culture time was 4 days. This was carried out by the method shown in Example 14.
- the pyripyropene analogs that were quantified were pyripyropene A, E, and O produced in this bacterium.
- Penicillium copirobium ATCC58615 which is the parent strain of the transformant, was similarly cultured and quantified for pyripyropene in the culture medium.
- Table 5 the pyripyropene productivity of the transformant was improved 2.5 times that of the parent strain.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
本発明は、ピリピロペン生合成遺伝子群と、マーカー遺伝子とを含む核酸構築物に関する。
ピリピロペンは、これまで側鎖の構造の違いにより、ピリピロペンA~Rまでの18種の類縁体が天然に存在することが明らかとされている(非特許文献1)。
目的物の生産性を向上させるためには、目的物生産微生物の培養方法の検討、培地成分の検討、および前駆体の添加などの発酵条件の改良、並びに紫外線照射または突然変異誘発剤による突然変異を利用した菌株の改良が行われている。さらに近年では、これらの方法に加えて遺伝子組換えを利用した生産性の向上も行われるようになってきた。
プラスミドpCC1-PP1で形質転換された大腸菌(Escherichia coli EPI300TM-T1R)は、2008年10月9日(原寄託日)付で独立行政法人産業技術総合研究所特許生物寄託 センター(〒305-8566 日本国茨城県つくば市東1丁目1番地1 中央第6)に、受託番号がFERM BP-11133(国内寄託FERM P-21704より移管)(寄託者が付した識別のための表示:Escherichia coli EPI300TM-T1R/pCC1-PP1)として寄託されている。
本発明におけるピリピロペン生合成遺伝子群とは、後述するマーカー遺伝子と宿主において発現可能な状態で核酸構築物中に配置されるものであり、ピリピロペンの生合成に関与する遺伝子群であれば特に限定されないが、好ましくは、下記の(I)~(IV)に記載されたヌクレオチド配列から選択された少なくとも1個のヌクレオチド配列の全長もしくはその一部を含んでなる構築物が提供される:
(I)配列番号266における2911番から27797番までのヌクレオチド配列、
(II)配列番号266における2911番から27797番までのヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(III) 配列番号266における2911番から27797番までのヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、および
(IV) 配列番号266における2911番から27797番までのヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列。
(1) 下記(a)-(i)に記載されたヌクレオチド配列:
(a)配列番号266で示されるヌクレオチド配列の3342番から5158番までのヌクレオチド配列、
(b)配列番号266で示されるヌクレオチド配列の5382番から12777番までのヌクレオチド配列、
(c)配列番号266で示されるヌクレオチド配列の13266番から15144番までのヌクレオチド配列、
(d)配列番号266で示されるヌクレオチド配列の16220番から18018番までのヌクレオチド配列、
(e)配列番号266で示されるヌクレオチド配列の18506番から19296番までのヌクレオチド配列、
(f)配列番号266で示されるヌクレオチド配列の19779番から21389番までのヌクレオチド配列、
(g)配列番号266で示されるヌクレオチド配列の21793番から22877番までのヌクレオチド配列、
(h)配列番号266で示されるヌクレオチド配列の23205番から24773番までのヌクレオチド配列、および
(i)配列番号266で示されるヌクレオチド配列の25824番から27178番までのヌクレオチド配列、
(2) (1)において記載されたヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列。
(1) 上記(a)-(i)または(a)-(h)に記載されたヌクレオチド配列の全長を全て含むヌクレオチド配列、
(2) (1)において記載されたヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列。
(1) 下記(j)-(s)に記載されたヌクレオチド配列の全長もしくは一部:
(j)配列番号266で示されるヌクレオチド配列の2911番から3341番までのヌクレオチド配列
(k)配列番号266で示されるヌクレオチド配列の5159番から5381番までのヌクレオチド配列
(l)配列番号266で示されるヌクレオチド配列の12778番から13265番までのヌクレオチド配列
(m)配列番号266で示されるヌクレオチド配列の15145番から16219番までのヌクレオチド配列
(n)配列番号266で示されるヌクレオチド配列の18019番から18505番までのヌクレオチド配列
(o)配列番号266で示されるヌクレオチド配列の19297番から19778番までのヌクレオチド配列
(p)配列番号266で示されるヌクレオチド配列の21390番から21792番までのヌクレオチド配列
(q)配列番号266で示されるヌクレオチド配列の22878番から23204番までのヌクレオチド配列
(r)配列番号266で示されるヌクレオチド配列の24774番から25823番までのヌクレオチド配列
(s)配列番号266で示されるヌクレオチド配列の27179番から27797番までのヌクレオチド配列
(2)(1)において記載されたヌクレオチド配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列。
(1) 前記(j)-(s)または(j)-(r)に記載されたヌクレオチド配列の全長を全て含むヌクレオチド配列、
(2)(1)において記載されたヌクレオチド配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列。
本発明において、ピリピロペンとは、ピリピロペンAからRまでを含む意味で用いられるものとし、好ましくは、ピリピロペンA、E、およびOであり、さらに好ましくはピリピロペンAである。
ピリピロペン生合成遺伝子群は、例えば、以下の方法で単離することができる。例えば、ピリピロペン生産菌のゲノムDNAを抽出し、適当な制限酵素にて切断後、コスミドベクターを用いて、ゲノムDNAからなるライブラリーを作製する。続いて、実施例12の記載に従ってcytochrome P450等のピリピロペン生合成遺伝子群に含まれるヌクレオチド配列を基に、適当なプライマーを合成し、それを用いてピリピロペン生産菌由来のゲノムDNAを鋳型としたPCR法を実施し、生合成遺伝子群の一部からなるDNA断片を増幅する。このDNA断片をプローブとして用い、ゲノムライブラリーのスクリーニングを行い、ピリピロペン生合成遺伝子群の全長もしくは一部を単離することができる。
本発明によるマーカー遺伝子は、上述したピリピロペン生合成遺伝子群と宿主において発現可能な状態で核酸構築物中に配置されるものであり、形質転換体の選択手法に応じて適宜選択できるが、例えば、薬剤耐性をコードする遺伝子や栄養要求性を相補する遺伝子を使用することができる。薬剤耐性遺伝子としては、例えば、デストマイシン、ハイグロマイシン、ベノミル、オリゴマイシン、G418、ブレオマイシン、ビアラホス、ブラストサイジンS、フレオマイシン、フォスフィノスリシン、アンピシリン、カナマイシン等の薬剤に対する遺伝子が挙げられ、好ましくはデストマイシン耐性遺伝子またはハイグロマイシン耐性遺伝子が挙げられる。栄養要求性を相補する遺伝子としては、例えば、amdS、pyrG、argB、trpC、niaD、TRP1、LEU2、URA3等の遺伝子が挙げられる。
本発明における核酸構築物は、宿主の遺伝子に導入できればどのような形態のものでもよいが、好ましくは、宿主への導入の際に、ベクター中に組み込まれた形態で用いることができる。従って、本発明好ましい態様によれば、本発明による核酸構築物を含んでなる組換えベクターが提供される。
本発明において使用できる宿主としては、本発明の核酸構築物を導入してピリピロペンを生産できる宿主であれば特に限定されないが、本発明の核酸構築物を導入しない状態でもピリピロペンを生産できる微生物が好ましく、より好ましくは糸状菌が挙げられ、さらに好ましくはペニシリウム属、ユーペニシリウム属、またはアスペルギルス属に属する微生物が挙げられ、さらに一層好ましくはペニシリウム コピロビウム、ペニシリウム グリセオフルバム、ユーペニシリウム レティキュロスポラム、またはアスペルギルス フミガタスが挙げられ、その中でもペニシリウム コピロビウムが好ましく、最も好ましくはペニシリウム コピロビウムPF1169株が挙げられる。
本発明によれば、前記宿主を、前記核酸構築物を用いて形質転換することにより、ピリピロペン生合成遺伝子群が導入された形質転換体が提供される。核酸構築物の宿主への導入方法は、宿主へ導入されれば特に限定されないが、例えば組換えベクターを用いた以下の方法により核酸構築物を宿主へ導入することができる。
本発明によれば、前記で造出された形質転換体を培養し、その培養物からピリピロペンを採取することを含んでなるピリピロペンの製造法、好ましくはピリピロペンの大量製造法が提供される。
三角フラスコ(1L)に滅菌したNB培地 500mlを入れ、1/2CMMY寒天培地において、28℃で、4日間前培養していたペニシリウム コピロビウムPF1169株(公開技報2008-500997号(特許文献4))を上記の培地に加え、28℃で、4日間液体培養した。ミラクロスで濾過により、菌体5gを得た。この菌体よりゲノムDNA精製キット Genomic-tip 100/G(キアゲン株式会社製)を、添付のマニュアルに従い、30μgのゲノムDNAを取得した。
種々の糸状菌ポリケチド合成酵素に保存されているアミノ酸配列より増幅用縮重プライマーとして 下記プライマーをデザインし、合成した:
LC1 : GAYCCIMGITTYTTYAAYATG(配列番号1)
LC2c: GTICCIGTICCRTGCATYTC(配列番号2)
(ただし、R=A/G、Y=C/T、M=A/C、I=イノシン)。
この縮重プライマーを使用して、実施例1において調製したゲノムDNAと、ExTaqポリメラーゼ(タカラバイオ株式会社製)とを、添付のマニュアルに従い反応させ、約700bpの増幅断片を検出した(図1)。そして、前記増幅断片を解析し、その内部500bpの配列を特定した(配列番号3)。
実施例1において得られたペニシリウム コピロビウムPF1169株のゲノムDNAを大量シークエンスと、アミノ酸配列の相同性検索とに供した。具体的にはゲノムDNA 50μgの一部を前処理の後、Roche社454FLX DNAシークエンサーに供し、約250bp、10.3万本のフラグメント配列(総計49Mbの配列)を取得した。
実施例3において取得したblastxの検索結果より、ポリケチド合成酵素に対して、配列番号227~252に示す13種のプライマー対を合成した。同様に、プレニルトランスフェラーゼに対して、配列番号253~262に示す5種のプライマー対を合成した。これらのプライマーを用いて、ゲノムDNAに対するPCRを行ったところ、全プライマー対について期待される大きさの増幅断片を認めた(図1および図2参照)。
ペニシリウム コピロビウムPF1169株のλファージゲノムライブラリーを、λBlueSTAR Xho I Half-site Arms Kit ( タカラバイオ株式会社製 Cat. No. 69242-3)を用いて、添付のマニュアルに従い、構築した。すなわち、ゲノムDNAを、制限酵素Sau3A1を用いて部分分解し、約20kbのDNA断片0.5μgをキットに添付されたλBlueSTAR DNA0.5μgに連結した。このライゲーション溶液をLambda INN Packaging kit(株式会社ニッポンジーン製)を用い、キットに添付のマニュアルに基づいてin vitroパッケージングを行い、1mlの溶液を取得した。このパッケージングされたファージ溶液10μlを大腸菌ER1647株100μlに感染させ、プラーク形成培地において、37℃で、一晩培養後、約500クローンのプラークを得た。このように感染により10~20kbのペニシリウム コピロビウムPF1169株のゲノム DNA が導入されたファージ約50000クローンからなるゲノムライブラリーを作製した。
実施例5において調製したファージライブラリー10000クローンに対して、上記で調製したLC1-LC2cプライマー対により増幅させたPCR産物をプローブとして、プラークハイブリダイゼーションによる1次スクリーニングを行った。プローブの標識と検出にはAlkPhos Direct Labelling and Detection System with CDP-Star(GEヘルスケア株式会社製 Cat. No. RPN3690)を用いた。前記ハイブリダイゼーションは、添付のマニュアルに従い、実施した。
ペニシリウム コピロビウムPF1169株のゲノムライブラリーは、CopyControl Fosmid Library Production Kit(EPICENTRE社製、Cat. No.CCFOS110)を、添付のマニュアルに従い、構築した。すなわち、約40 kbのゲノムDNA0.25μgのDNA断片を末端の平滑化を行った後、フォスミドベクターpCCFOS(Epicentre社製)に組み込んだ。このライゲーション溶液を同キット添付のMaxPlaxLambda Packaging Extractを用い、キットに添付のマニュアルに基づいて、in vitroパッケージングを行った。このパッケージングされたウィルス溶液10μlを大腸菌EPI300TM-T1R株100μlに感染させ、クロラムフェニコール含有培地において、37℃で、一晩培養し選抜したところ、300クローンのコロニーを得た。このように感染により40kbのペニシリウム コピロビウムPF1169株のゲノムDNA が導入されたフォスミド約30000クローンを取得した。1wellあたり約50クローンとなるように96wellプレートに分注し、つまり、96のプール、約4800クローンからなるゲノムライブラリーを作製した。
フォスミド添付のマニュアルに従い、実施例7において作成したライブラリーの96プールより各プラスミドDNAを調製した。実施例2で合成したポリケチド合成酵素増幅用縮重プライマーを用いて、この96プールのプラスミドDNAサンプルに対して、PCRを行った。その結果、約700bpのDNA断片が、9プールより増幅した。さらにこのポジティブプールから、約300クローン以上のコロニーを含むシャーレを作製し、コロニーハイブリダイゼーションにより再スクリーニングした。その結果、LC1-LC2cプライマー対を用いて、約4800クローンより9種のフォスミドを取得した。
実施例1において得られたペニシリウム コピロビウムPF1169株のゲノムDNAを大量シークエンスと、アミノ酸配列の相同性検索とに供した。具体的にはゲノムDNA 50μgの一部を前処理の後、Roche社454FLX DNAシークエンサーに供し、平均コンティグ長19.621kb、1405本のフラグメント配列(総塩基長27.568160Mbの配列)を取得した。
この配列に対し、ポリケチド合成酵素およびプレニルトランスフェラーゼで既知である配列として、下記の五種の配列(ポリケチド合成酵素: Penicillium(P.) griseofluvum 6-methylsalycilic acid synthase 1744a.a.(P22367) およびAspergillus(A.) fumigatus PKS 2146a.a.(Q4WZA8)、プレニルトランスフェラーゼ:Penicillium(P.) marneffei Prenyltransferase(Q0MRO8)、Aspergillus(A.) fumigatus Prenyltransferase(Q4WBI5)、およびAspergillus(A.) fumigatus Prenyltransferase(4-hydroxybezoate octaprenyltransferase)(Q4WLD0)由来の配列)を選定し、相同配列検索ソフトblastxによる検索を実施した。それぞれ22本(P22367)、21本(Q4WZA8)、2本(Q0MRO8)、3本(Q4WBI5)、および3本(Q4WLD0)の相同配列を取得した。
得られたpCC1-PP1により大腸菌Escherichia coli EPI300TM-T1R株(フォスミドキットに付属)を形質転換することにより大腸菌Escherichia coli EPI300TM-T1R株/pCC1-PP1(受託番号FERM BP-11133)を得た。
なお、前記配列番号266の配列とCoA ligase、LovB-like polyketide synthase(PKS)、水酸化酵素であるCytochrome P450 monooxygenase、Cyclase、FAD-dependent monooxygenase(FMO)、UbiA-like prenyltransferase(UbiAPT)、アセチル化酵素であるAcetyltransferase(AT)、Acetyltransferase-2(AT-2)、およびCation transporting ATPase(上記酵素は、いずれもAspergillus fumigatus Af293株由来)との、相同性検索をそれぞれ行ったところ、いずれも70%以上の高い相同性を示した。
配列番号266のヌクレオチド3342-5158は、CoA ligaseをコードし、その対応するポリペプチドは、配列番号267に記載したアミノ酸配列で示され、配列番号266のヌクレオチド5382-12777は、LovB-like polyketide synthase(PKS)をコードし、対応するポリペプチドは、配列番号268に記載したアミノ酸配列で示され、配列番号266のヌクレオチド13266-15144(以下、このポリヌクレオチド配列(P450-1)によりコードされるタンパク質をCytochrome P450 monooxygenase(1)とする)および16220-18018(以下、このポリヌクレオチド配列(P450-2)によりコードされるタンパク質をCytochrome P450 monooxygenase(2)とする)は、Cytochrome P450 monooxygenaseをコードし、対応するポリペプチドは、それぞれ、配列番号269、270に記載したアミノ酸配列で示され、配列番号266のヌクレオチド18506-19296は、Cyclaseをコードし、対応するポリペプチドは、配列番号271に記載したアミノ酸配列で示され、配列番号266のヌクレオチド19779-21389は、FAD-dependent monooxygenase(FMO)をコードし、対応するポリペプチドは、配列番号272に記載したアミノ酸配列で示され、配列番号266のヌクレオチド21793-22877は、UbiA-like prenyltransferase(UbiAPT)をコードし、対応するポリペプチドは、配列番号273に記載したアミノ酸配列で示され、配列番号266のヌクレオチド23205-24773は、Acetyltransferase(AT)をコードし、対応するポリペプチドは、配列番号274に記載したアミノ酸配列で示され、配列番号266のヌクレオチド25824-27178は、Acetyltransferase-2(AT-2)をコードし、対応するポリペプチドは、配列番号275に記載したアミノ酸配列で示され、配列番号266のヌクレオチド27798-31855は、Cation transporting ATPaseをコードし、対応するポリペプチドは、配列番号276に記載したアミノ酸配列で示された。
カビの形質転換が可能なコスミドベクターpMFCOS1を以下のようにして構築した。プラスミドpMKD01(特許第3593134号公報)よりカビの形質転換用マーカー遺伝子であるデストマイシン耐性遺伝子を含む約3.0kbのXbaI断片を調製し、T4ポリメラーゼを使用して末端を平滑化した。この断片を制限酵素SmaIおよびStuIで二重消化した市販のコスミドベクターSuperCos1(ストラタジーン社)と連結してコスミドベクターpMFCOS1を構築した。
実施例1で作製したゲノムDNAライブラリーをスクリーニングするためのプローブとして、ピリピロペンA生合成遺伝子の一つであるcytochrome P450遺伝子を使用することとし、以下に示すようにPCRによって調製した。
ピリピロペン生産菌であるペニシリウム コピロビウム PF1169株を液体培地(3%グリセリン、0.8%ニュートリエントブロス、0.3%麦芽エキス、0.2%酵母エキス、0.1%グルタミン酸ナトリウム、2.0%グリシン、pH7.0)に植菌し、26℃、24時間培養した後、遠心により菌体を集めた。得られた菌体を1.0M KClで洗浄し、0.45μmのフィルターで濾過したプロトプラスト化酵素溶液(3mg/mL β-glucuronidase、1mg/mL Chitinase、3mg/mL Lysing enzyme、1.0M KCl)10mLに懸濁した。30℃で60~90分間振盪し、菌糸をプロトプラスト化させた。この懸濁液を濾過した後、遠心してプロトプラストを回収し、SUTC緩衝液(0.5mol/Lシュークロース、10mM 塩化カルシウム、10mM トリス塩酸[pH7.5])で洗浄した。
形質転換体の培養には、種培地として2.0%でんぷん(スターチ)、1.0%ぶどう糖(グルコース)、0.5%ポリペプトン、0.6%小麦胚芽、0.3%酵母エキス、0.2%大豆粕および炭酸カルシウム0.2%の組成からなる培地(殺菌前pH7.0)を用いた。また、生産培地としては、10.0%グルコース、1.3%脱脂大豆、0.3%グルタミン酸ナトリウム、0.8%小麦胚芽、0.125%塩化ナトリウム、0.15%炭酸カルシウム、0.2%ニコチンアミドの組成からなる培地(殺菌前pH7.0)を用いた。
1/2CMMY寒天培地でペニシリウム コピロビウムPF1169株を28℃で3日間培養し、分生糸をかきとり回収した。滅菌ミラクロス(Carbiochem社製、Cat, No. 475855)で濾過して胞子を取得し、IM液体培地(1.74 g/L K2HPO4、1.36 g/L KH2PO4、0.14 g/L NaCl、0.49 g/L MgSO4・7H2O、0.10 g/L CaCl2・2H2O、100 μL/L 9 mM FeSO4、0.53 g/l (NH4)2SO2、1.8 g/L グルコース、8.53 g/L MES (2-Morpholinoethanesulfonic acid)、5 mL/L グリセリン、pH 5.3)で103 /mlに希釈し、これをペニシリウム コピロビウム胞子懸濁液とした。
実施例12で得たpPYRI02の挿入断片末端の塩基配列は、配列番号266の1~25000およびその上流域を含む配列である。さらにピリピロペン生合成遺伝子クラスターの下流部分を加えた全長のピリピロペン生合成遺伝子クラスターを得るために、別途クローニングした生合成遺伝子クラスターの下流部分と、上記pPYRI02の挿入断片と連結させることにより、全長の生合成遺伝子クラスターを構築することとした。
実施例12で得たpPYRI02の挿入断片と、前記pPYRI03の挿入断片を用い、生合成遺伝子クラスター全長を有するコスミドを構築することとした。それぞれのコスミドの塩基配列の解析よりクラスター上に有する制限酵素部位が明らかにでき、生合成遺伝子クラスターの上流領域としてpPYRI02のBsiWI断片(約20.2kb)を、下流領域としてpPYRI03のBsiWI~AflII断片(約4.9kb)を連結することにより、全長の生合成遺伝子クラスーが構築できることが明らかとなった。
そこでまず、放線菌の接合伝達用プラスミドpSET152[ビアマン(Bierman,M.)ら著,「ジーン(Gene)」,(蘭国),1992年,第116巻,p.43-49]をSphI 消化し、T4 DNA ポリメラーゼで平滑化した後、HindIII リンカー(5’-CCCAAGCTTGGG-3’(配列番号281)、宝酒造株式会社製)を連結してプラスミドpSET153 を構築した。pSET153のマルチクローニングサイトをHindIII-NotI-BsiWIAflII-NotI-EcoRI に変更するため、合成オリゴヌクレオチドHin-Not-Bsi-Afl-Not-Eco-1(5’-AGCTTGCGGCCGCGTACGCTTAAGGCGGCCGCG-3’)(配列番号282)およびHin-Not-Bsi-Afl-Not-Eco-2(5’-AATTCGCGGCCGCCTTAAGCGTACGCGGCCGCA-3’)(配列番号283)をアニールした後、HindIII 及びEcoRI で二重消化したpSET153 と連結してプラスミドpSET201 を構築した。pSET201 のBsiWI-AflII 部位に、pPYRI03 由来の約4.9kb のBsiWI-AflII 断片を挿入してプラスミドpPYRI05 を得た。pPYRI05 のBsiWI 部位に、pPYRI02由来の約20.2kb のBsiWI 断片を挿入し、BsiWI 断片が天然の生合成遺伝子クラスターと同向きに挿入されたクローンを選抜し、プラスミドpPYRI06 を得た。pPYRI06 は生合成遺伝子クラスター全長を含むプラスミドであるが、カビの形質転換マーカーを有していないことから、挿入断片のコスミドベクターpMFCOS1 への繋ぎ換えを行った。即ち、pPYRI02由来の約8.5kb のコスミドベクター部分のNotI 断片と、pPYRI06 由来の約25.1kb のNotI断片を連結してコスミドpPYRI07(翻訳領域:配列番号284、非翻訳領域:配列番号285)を得た。pPYRI07 は生合成遺伝子クラスター全長を含むとともにカビの形質転換マーカー遺伝子も有するコスミドである。
pPYRI07 の挿入断片末端の塩基配列を解析した結果、配列番号266の2446~27505およびその上流にベクター部分の塩基配列を含んでおり、全長のピリピロペン生合成遺伝子クラスターを含むことが確認された。
実施例16で得たpPYRI07を用いた以外は、実施例13の場合と同様の条件で形質転換体の造出を行った。
実施例17で得られ形質転換体の培養および培養液中のピリピロペンの定量方法は、実施例14で示した方法にて行った。定量を行ったピリピロペン類縁体は、本菌において産生されているピリピロペンA、E、Oとした。また同時に形質転換体の親株であるペニシリウム コピロビウム PF1169株についても、同様に培養及び培養液中のピリピロペンの定量を行った。
その結果、下表4に示したとおり、形質転換体のピリピロペン生産性は、親株の3.6倍に向上していた。以上の結果から、全長のピリピロペン生合成遺伝子クラスターの導入により、ペニシリウム コピロビウム PF1169株の生産性が向上することが示された。
ペニシリウム コピロビウム PF1169株以外のペニシリウム コピロビウムにおいても全長のピリピロペン生合成遺伝子クラスターを導入により、その生産性が向上することを確認するために、ペニシリウム コピロビウムATCC58615株(Studies in Mycology(2004), 49 p84-85参照)について形質転換を行った。
実施例19で得られ形質転換体の培養および培養液中のピリピロペンの定量方法は、培養時間が4日間であることを除き、実施例14で示した方法にて行った。定量を行ったピリピロペン類縁体は、本菌において産生されているピリピロペンA、E、Oとした。また同時に形質転換体の親株であるペニシリウム コピロビウムATCC58615株についても、同様に培養および培養液中のピリピロペンの定量を行った。
その結果、下表5に示したとおり、形質転換体のピリピロペン生産性は、親株の2.5倍に向上していた。以上の結果から、全長のピリピロペン生合成遺伝子クラスターの導入により、PF1169株以外のペニシリウム コピロビウムについても、その生産性が向上することが示された。また、ペニシリウム コピロビウムPF1169株の方が、ペニシリウム コピロビウムATCC58615株に比べ、生産性がより向上するが明らかとなった。
FERM BP-11203
FERM BP-11316
Claims (17)
- ピリピロペン生合成遺伝子群と、マーカー遺伝子とを含む、核酸構築物。
- 前記ピリピロペン生合成遺伝子群が、下記の(I)~(IV)に記載されたヌクレオチド配列から選択された少なくとも1個のヌクレオチド配列の全長もしくはその一部を含んでなる、請求項1に記載の核酸構築物:
(I)配列番号266における2911番から27797番までのヌクレオチド配列、
(II)配列番号266における2911番から27797番までのヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(III) 配列番号266における2911番から27797番までのヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、および
(IV) 配列番号266における2911番から27797番までのヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつ配列番号266における2911番から27797番までのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列。 - 前記ピリピロペン生合成遺伝子群が、目的遺伝子と、発現調節領域とを含んでなる、請求項1または2に記載の核酸構築物。
- 前記目的遺伝子が、配列番号267~275から選択される少なくとも一つのアミノ酸配列またはそれと実質的に同等なアミノ酸配列をコードするヌクレオチド配列を含む、請求項3に記載の核酸構築物。
- 前記目的遺伝子が、下記の(1)~(4)に記載されたヌクレオチド配列から選択された少なくとも1個のヌクレオチド配列を含む、請求項3に記載の核酸構築物:
(1)下記(a)-(i)に記載されたヌクレオチド配列:
(a)配列番号266で示されるヌクレオチド配列の3342番から5158番までのヌクレオチド配列、
(b)配列番号266で示されるヌクレオチド配列の5382番から12777番までのヌクレオチド配列、
(c)配列番号266で示されるヌクレオチド配列の13266番から15144番までのヌクレオチド配列、
(d)配列番号266で示されるヌクレオチド配列の16220番から18018番までのヌクレオチド配列、
(e)配列番号266で示されるヌクレオチド配列の18506番から19296番までのヌクレオチド配列、
(f)配列番号266で示されるヌクレオチド配列の19779番から21389番までのヌクレオチド配列、
(g)配列番号266で示されるヌクレオチド配列の21793番から22877番までのヌクレオチド配列、
(h)配列番号266で示されるヌクレオチド配列の23205番から24773番までのヌクレオチド配列、および
(i)配列番号266で示されるヌクレオチド配列の25824番から27178番までのヌクレオチド配列、
(2) (1)において記載されたヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそれぞれのヌクレオチド配列がコードするタンパク質と実質的に同等なタンパク質をコードするヌクレオチド配列。 - 前記発現調節領域が、下記の(1)~(4)に記載されたヌクレオチド配列から選択された少なくとも1個ヌクレオチド配列を含む、請求項3~5のいずれか一項に記載の核酸構築物:
(1)下記(j)-(s)に記載されたヌクレオチド配列の全長もしくはその一部:
(j)配列番号266で示されるヌクレオチド配列の2911番から3341番までのヌクレオチド配列、
(k)配列番号266で示されるヌクレオチド配列の5159番から5381番までのヌクレオチド配列、
(l)配列番号266で示されるヌクレオチド配列の12778番から13265番までのヌクレオチド配列、
(m)配列番号266で示されるヌクレオチド配列の15145番から16219番までのヌクレオチド配列、
(n)配列番号266で示されるヌクレオチド配列の18019番から18505番までのヌクレオチド配列、
(o)配列番号266で示されるヌクレオチド配列の19297番から19778番までのヌクレオチド配列、
(p)配列番号266で示されるヌクレオチド配列の21390番から21792番までのヌクレオチド配列、
(q)配列番号266で示されるヌクレオチド配列の22878番から23204番までのヌクレオチド配列、
(r)配列番号266で示されるヌクレオチド配列の24774番から25823番までのヌクレオチド配列、および
(s)配列番号266で示されるヌクレオチド配列の27179番から27797番までのヌクレオチド配列、
(2) (1)において記載されたヌクレオチド配列の相補配列と厳密な条件下でハイブリダイズ可能なヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(3)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドにおいて、1もしくは複数個のヌクレオチドが欠失、置換、挿入もしくは付加されたヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列、
(4)(1)において記載されたヌクレオチド配列からなるポリヌクレオチドと少なくとも90%以上の同一性を有するヌクレオチド配列であり、かつそれぞれのヌクレオチド配列と実質的に同等な機能を有するヌクレオチド配列。 - 前記マーカー遺伝子が、薬剤耐性遺伝子または栄養要求性遺伝子である、請求項1~6に記載の核酸構築物。
- 前記マーカー遺伝子が、デストマイシン耐性遺伝子またはハイグロマイシン耐性遺伝子である、請求項1~6に記載の核酸構築物。
- 請求項1~8のいずれか一項に記載の核酸構築物を、宿主に導入することにより得られる、形質転換体。
- ピリピロペン生合成遺伝子群を含む核酸構築物と、マーカー遺伝子を含む核酸構築物とを、同時にまたは別々に、宿主に導入することにより得られる、形質転換体。
- プラスミドpPYRI02またはコスミドpPYRI07を宿主に導入することにより得られる、請求項9に記載の形質転換体。
- 前記宿主がピロピロペンを生産する糸状菌である、請求項9~11のいずれか一項に記載の形質転換体。
- 前記ピリピロペンを生産する糸状菌が、ペニシリウム属、ユーペニシリウム属、またはアスペルギルス属である、請求項12に記載の形質転換体。
- 前記ピリピロペンを生産する糸状菌が、ペニシリウム コピロビウム、ペニシリウム グリセオフルバム、ユーペニシリウム レティキュロスポラム、アスペルギルス フミガタスである、請求項12に記載の形質転換体。
- 前記ピリピロペンを生産する糸状菌がペニシリウム コピロビウムである、請求項12に記載の形質転換体。
- 前記ピリピロペンを生産する糸状菌がペニシリウム コピロビウムPF1169 株またはペニシリウム コピロビウムATCC58615株である、請求項12に記載の形質転換体。
- 請求項9~16のいずれか一項に記載の形質転換体を培養し、培養物からピリピロペンを採取することを含んでなる、ピリピロペンの製造法。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011210968A AU2011210968B2 (en) | 2010-01-26 | 2011-01-19 | Nucleic acid structure containing a pyripyropene biosynthesis gene cluster and a marker gene |
DK11736900.9T DK2530149T3 (en) | 2010-01-26 | 2011-01-19 | Nucleic acid structure containing a pyripyropene biosynthesis gene cluster and a marker gene |
EP11736900.9A EP2530149B1 (en) | 2010-01-26 | 2011-01-19 | Nucleic acid structure containing a pyripyropene biosynthesis gene cluster and a marker gene |
NZ601951A NZ601951A (en) | 2010-01-26 | 2011-01-19 | Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene |
US13/575,145 US9090924B2 (en) | 2010-01-26 | 2011-01-19 | Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene |
CN201180007186.8A CN102884187B (zh) | 2010-01-26 | 2011-01-19 | 包含啶南平生物合成基因簇和标记基因的核酸构建体 |
PL11736900T PL2530149T3 (pl) | 2010-01-26 | 2011-01-19 | Struktura kwasu nukleinowego zawierająca klaster genów biosyntezy pirypiropenu i gen markerowy |
ES11736900.9T ES2655615T3 (es) | 2010-01-26 | 2011-01-19 | Estructura de ácido nucleico que contiene un grupo de genes de biosintesis de piripiropeno y un gen marcador |
BR112012019458A BR112012019458B8 (pt) | 2010-01-26 | 2011-01-19 | construção de ácidos nucleicos, transformante, e métodos para produzir piripiropenos |
MX2012008687A MX340373B (es) | 2010-01-26 | 2011-01-19 | Estructura de acido nucleico que contiene un agrupamiento de genes para la biosintesis de piripiropeno y un gen marcador. |
JP2011551816A JP5864267B2 (ja) | 2010-01-26 | 2011-01-19 | ピリピロペン生合成遺伝子群およびマーカー遺伝子を含む核酸構築物 |
KR1020177028393A KR101831121B1 (ko) | 2010-01-26 | 2011-01-19 | 피리피로펜 생합성 유전자 클러스터 및 표지 유전자를 포함하는 핵산 구성체 |
CA2788080A CA2788080C (en) | 2010-01-26 | 2011-01-19 | Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene |
RU2012136448/10A RU2576001C2 (ru) | 2010-01-26 | 2011-01-19 | Конструкции нуклеиновой кислоты, содержащие кластер генов биосинтеза пирипиропена и маркерный ген |
IL221129A IL221129B (en) | 2010-01-26 | 2012-07-26 | Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-014700 | 2010-01-26 | ||
JP2010014700 | 2010-01-26 | ||
JP2010253183 | 2010-11-11 | ||
JP2010-253183 | 2010-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011093186A1 true WO2011093186A1 (ja) | 2011-08-04 |
Family
ID=44319176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/050852 WO2011093186A1 (ja) | 2010-01-26 | 2011-01-19 | ピリピロペン生合成遺伝子群およびマーカー遺伝子を含む核酸構築物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9090924B2 (ja) |
EP (1) | EP2530149B1 (ja) |
JP (1) | JP5864267B2 (ja) |
KR (2) | KR101831121B1 (ja) |
CN (1) | CN102884187B (ja) |
AU (1) | AU2011210968B2 (ja) |
BR (1) | BR112012019458B8 (ja) |
CA (1) | CA2788080C (ja) |
DK (1) | DK2530149T3 (ja) |
ES (1) | ES2655615T3 (ja) |
IL (1) | IL221129B (ja) |
MX (1) | MX340373B (ja) |
NZ (1) | NZ601951A (ja) |
PL (1) | PL2530149T3 (ja) |
RU (1) | RU2576001C2 (ja) |
TW (1) | TWI633185B (ja) |
WO (1) | WO2011093186A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013073689A1 (ja) * | 2011-11-17 | 2013-05-23 | Meiji Seikaファルマ株式会社 | ピリピロペン生合成遺伝子発現植物体 |
JP5898960B2 (ja) * | 2010-01-26 | 2016-04-06 | Meiji Seikaファルマ株式会社 | ピリピロペンの製造法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116904328A (zh) * | 2023-07-13 | 2023-10-20 | 山东大学 | 一种高表达啶南平a的工程菌及发酵培养基 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0358566B2 (ja) | 1986-06-20 | 1991-09-05 | Horiuretan Kasei Kk | |
JPH04360895A (ja) | 1991-06-06 | 1992-12-14 | Kitasato Inst:The | Fo−1289a物質およびその製造法 |
JPH06184158A (ja) | 1992-10-22 | 1994-07-05 | Kitasato Inst:The | Fo−1289物質およびその製造法 |
WO2004060065A1 (en) | 2003-01-07 | 2004-07-22 | Korea Research Institute Of Bioscience And Biotechnology | Insecticidal compositions comprising compounds having inhibitory activity versus acyl coa: cholesterol acyltransferase or salts thereof as effective ingredients |
JP3593134B2 (ja) | 1996-07-24 | 2004-11-24 | 明治製菓株式会社 | フミコーラ属微生物におけるタンパク質またはペプチドの大量生産系 |
WO2006129714A1 (ja) | 2005-06-01 | 2006-12-07 | Meiji Seika Kaisha, Ltd. | 害虫防除剤 |
JP3961289B2 (ja) | 1999-09-07 | 2007-08-22 | 明治製菓株式会社 | 環状デプシペプチド合成酵素およびその遺伝子並びに環状デプシペプチドの大量生産系 |
WO2010010955A1 (ja) * | 2008-07-24 | 2010-01-28 | 明治製菓株式会社 | ピリピロペンa生合成遺伝子 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022454A1 (en) * | 1992-04-30 | 1993-11-11 | Institut Pasteur | Rapid detection of antibiotic resistance in mycobacterium tuberculosis |
US5712146A (en) * | 1993-09-20 | 1998-01-27 | The Leland Stanford Junior University | Recombinant combinatorial genetic library for the production of novel polyketides |
JP4114958B2 (ja) * | 1994-06-07 | 2008-07-09 | キヤノン株式会社 | 核酸ハイブリッド体の検出方法及びそれに用いるプローブ |
DE69532255D1 (de) * | 1994-05-26 | 2004-01-22 | Canon Kk | Verfahren zum Nachweis von einer Zielsubstanz in einer Probe mit Hilfe von Pyryliumverbindung |
JPH08239385A (ja) | 1995-03-03 | 1996-09-17 | Kitasato Inst:The | Fo−1289物質およびその製造法 |
JP3725198B2 (ja) | 1995-03-27 | 2005-12-07 | 社団法人北里研究所 | ピリピロペン誘導体 |
JPH08269063A (ja) | 1995-03-28 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269062A (ja) | 1995-03-30 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269064A (ja) | 1995-04-03 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269066A (ja) | 1995-04-03 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
JPH08269065A (ja) | 1995-04-03 | 1996-10-15 | Kitasato Inst:The | ピリピロペン誘導体 |
JP3688337B2 (ja) | 1995-04-18 | 2005-08-24 | 社団法人北里研究所 | ピリピロペン誘導体 |
US20060135664A1 (en) | 2004-12-17 | 2006-06-22 | David Glassel | Methods and compositions of matter for treatment of cellulose |
US20060135645A1 (en) | 2004-12-17 | 2006-06-22 | David Glassel | Pest protection methods and compositions |
US7491738B2 (en) | 2005-06-01 | 2009-02-17 | Meiji Seika Kaisha, Ltd. | Pest control agents |
WO2008066153A1 (fr) | 2006-11-30 | 2008-06-05 | Meiji Seika Kaisha, Ltd. | Agent antiparasitaire |
EP2592084B8 (en) | 2007-08-13 | 2014-08-27 | Basf Se | Process for producing pyripyropene derivatives and intermediates for the production thereof. |
-
2011
- 2011-01-19 BR BR112012019458A patent/BR112012019458B8/pt active IP Right Grant
- 2011-01-19 TW TW100102059A patent/TWI633185B/zh active
- 2011-01-19 JP JP2011551816A patent/JP5864267B2/ja active Active
- 2011-01-19 WO PCT/JP2011/050852 patent/WO2011093186A1/ja active Application Filing
- 2011-01-19 KR KR1020177028393A patent/KR101831121B1/ko active IP Right Grant
- 2011-01-19 PL PL11736900T patent/PL2530149T3/pl unknown
- 2011-01-19 ES ES11736900.9T patent/ES2655615T3/es active Active
- 2011-01-19 DK DK11736900.9T patent/DK2530149T3/en active
- 2011-01-19 RU RU2012136448/10A patent/RU2576001C2/ru active
- 2011-01-19 CA CA2788080A patent/CA2788080C/en active Active
- 2011-01-19 US US13/575,145 patent/US9090924B2/en active Active
- 2011-01-19 NZ NZ601951A patent/NZ601951A/en unknown
- 2011-01-19 CN CN201180007186.8A patent/CN102884187B/zh active Active
- 2011-01-19 MX MX2012008687A patent/MX340373B/es active IP Right Grant
- 2011-01-19 AU AU2011210968A patent/AU2011210968B2/en active Active
- 2011-01-19 KR KR1020127021871A patent/KR20120107519A/ko active Search and Examination
- 2011-01-19 EP EP11736900.9A patent/EP2530149B1/en active Active
-
2012
- 2012-07-26 IL IL221129A patent/IL221129B/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0358566B2 (ja) | 1986-06-20 | 1991-09-05 | Horiuretan Kasei Kk | |
JPH04360895A (ja) | 1991-06-06 | 1992-12-14 | Kitasato Inst:The | Fo−1289a物質およびその製造法 |
JPH06184158A (ja) | 1992-10-22 | 1994-07-05 | Kitasato Inst:The | Fo−1289物質およびその製造法 |
JP3593134B2 (ja) | 1996-07-24 | 2004-11-24 | 明治製菓株式会社 | フミコーラ属微生物におけるタンパク質またはペプチドの大量生産系 |
JP3961289B2 (ja) | 1999-09-07 | 2007-08-22 | 明治製菓株式会社 | 環状デプシペプチド合成酵素およびその遺伝子並びに環状デプシペプチドの大量生産系 |
WO2004060065A1 (en) | 2003-01-07 | 2004-07-22 | Korea Research Institute Of Bioscience And Biotechnology | Insecticidal compositions comprising compounds having inhibitory activity versus acyl coa: cholesterol acyltransferase or salts thereof as effective ingredients |
WO2006129714A1 (ja) | 2005-06-01 | 2006-12-07 | Meiji Seika Kaisha, Ltd. | 害虫防除剤 |
WO2010010955A1 (ja) * | 2008-07-24 | 2010-01-28 | 明治製菓株式会社 | ピリピロペンa生合成遺伝子 |
Non-Patent Citations (10)
Title |
---|
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 61, no. 12, 1995, pages 4429 - 4435 |
BIERMAN, M. ET AL., GENE, vol. 116, 1992, pages 43 - 49 |
FEDOROVA N.D. ET AL: "Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus", PLOS GENET., vol. 4, no. 4, 2008, pages E1000046, XP002519164 * |
GO TSUJIUCHI ET AL.: "Pyripyropene-rui Seisanno o Yusuru Shinki Biseibutsu", JAPAN INSTITUTE OF INVENTION AND INNOVATION, JOURNAL OF TECHNICAL DISCLOSURE, JOURNAL NUMBER 2008-500997, 13 February 2008 (2008-02-13), XP009154054 * |
JOURNAL OF ANTIBIOTICS, vol. 49, no. 3, 1996, pages 292 - 298 |
MYCOLOGY, vol. 49, 2004, pages 84 - 85 |
NIERMAN W.C. ET AL: "Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus", NATURE, vol. 438, no. 7071, 2005, pages 1151 - 1156, XP008139207 * |
See also references of EP2530149A4 |
SUNAZUKA T. ET AL.: "Total synthesis of alpha-pyrone meroterpenoids, novel bioacti ve microbial metabolites", CHEM. REV., vol. 105, no. 12, 2005, pages 4559 - 4580, XP008139913 * |
TOMODA H. ET AL.: "Biosynthesis of Pyripyropene A", J. ORG. CHEM., vol. 61, no. 3, 1996, pages 882 - 886, XP008139912 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5898960B2 (ja) * | 2010-01-26 | 2016-04-06 | Meiji Seikaファルマ株式会社 | ピリピロペンの製造法 |
WO2013073689A1 (ja) * | 2011-11-17 | 2013-05-23 | Meiji Seikaファルマ株式会社 | ピリピロペン生合成遺伝子発現植物体 |
Also Published As
Publication number | Publication date |
---|---|
PL2530149T3 (pl) | 2018-04-30 |
RU2576001C2 (ru) | 2016-02-27 |
CA2788080C (en) | 2018-04-17 |
BR112012019458A2 (pt) | 2015-09-15 |
ES2655615T3 (es) | 2018-02-20 |
KR20170125947A (ko) | 2017-11-15 |
BR112012019458B1 (pt) | 2021-02-17 |
JPWO2011093186A1 (ja) | 2013-06-06 |
TW201139669A (en) | 2011-11-16 |
KR20120107519A (ko) | 2012-10-02 |
BR112012019458B8 (pt) | 2022-08-02 |
KR101831121B1 (ko) | 2018-02-21 |
AU2011210968B2 (en) | 2015-05-07 |
US9090924B2 (en) | 2015-07-28 |
IL221129B (en) | 2018-06-28 |
NZ601951A (en) | 2015-01-30 |
JP5864267B2 (ja) | 2016-02-17 |
EP2530149A1 (en) | 2012-12-05 |
AU2011210968A1 (en) | 2012-09-13 |
RU2012136448A (ru) | 2014-03-10 |
MX2012008687A (es) | 2012-08-23 |
DK2530149T3 (en) | 2017-12-04 |
EP2530149A4 (en) | 2014-01-15 |
TWI633185B (zh) | 2018-08-21 |
CA2788080A1 (en) | 2011-08-04 |
CN102884187B (zh) | 2017-03-01 |
US20130017581A1 (en) | 2013-01-17 |
MX340373B (es) | 2016-07-07 |
CN102884187A (zh) | 2013-01-16 |
EP2530149B1 (en) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2540017C2 (ru) | Выделенный полинуклеотид, кодирующий полипептид, вовлеченный в биосинтез пирипиропена а, вектор и клетка-хозяин содержащие такой полинуклеотид и способ получения предшественника пирипиропена а (варианты) | |
FI104264B (fi) | Menetelmä sekundääristen metaboliittien tuoton parantamiseksi käyttämällä rykelmöityjä biosynteettisiä geenejä | |
MX2012008637A (es) | Metodo para producir piripiropeno. | |
JP5864267B2 (ja) | ピリピロペン生合成遺伝子群およびマーカー遺伝子を含む核酸構築物 | |
US9771606B2 (en) | UK-2 biosynthetic gene and method for improving UK-2 productivity using the same | |
JP4216183B2 (ja) | サポニン分解酵素、その遺伝子およびソヤサポゲノールbの大量生産系 | |
CN113846041B (zh) | 增强转运蛋白基因的表达以提高盐霉素发酵水平的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180007186.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11736900 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011551816 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2788080 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/008687 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201003747 Country of ref document: TH Ref document number: 221129 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011210968 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20127021871 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7353/DELNP/2012 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2011736900 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011736900 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012136448 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2011210968 Country of ref document: AU Date of ref document: 20110119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13575145 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012019458 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012019458 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120726 |